ADVENTRX to Present at Informed Investors Bay Area Biotechnology and Healthcare Forum
December 01 2005 - 8:30AM
PR Newswire (US)
SAN DIEGO, Dec. 1 /PRNewswire-FirstCall/ -- ADVENTRX
Pharmaceuticals, Inc. (AMEX:ANX) today announced that Brian M.
Culley, vice president of business development, will present a
corporate overview at the Informed Investors Bay Area Biotechnology
and Healthcare Forum on Wednesday, December 7th at 9:40 am PST, at
The Hyatt Regency in San Francisco. For more information about this
conference and to access a live slide and audio webcast of Mr.
Culley's presentation, visit
http://www.investorcalendar.com/IIF/CustomEvent/90563/index.asp.
Presentations from the forum will be archived at
http://www.investorcalendar.com/IIF/CustomEvent/90563/index.asp.
About ADVENTRX ADVENTRX Pharmaceuticals is a biopharmaceutical
research and development company focused on introducing new
technologies for anticancer and antiviral treatments that improve
the performance and safety of existing drugs by addressing
significant problems such as drug metabolism, toxicity,
bioavailability and resistance. The Company's lead compound,
CoFactor(TM), is a biomodulator of 5-fluorouracil (5-FU), a widely
used cancer chemotherapy agent. Phase II and Phase IIb clinical
trials are ongoing to evaluate CoFactor use with 5-FU as a first
line treatment of metastatic colorectal cancer. The Company has
received clearance under a special protocol assessment from the US
Food and Drug Administration (FDA) to begin a CoFactor Phase III
pivotal clinical trial for metastatic colorectal cancer, which is
currently planned to begin patient dosing in Q1 2006. More
information can be found on the Company's Web site at
http://www.adventrx.com/. Forward Looking Statement This press
release contains forward-looking statements, within the meaning of
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995, regarding ADVENTRX. Such statements are made
based on management's current expectations and beliefs. Actual
results may vary from those currently anticipated based upon a
number of factors, including uncertainties inherent in the drug
development process, the timing and success of clinical trials, the
validity of research results, and the receipt of necessary
approvals from the FDA and other regulatory agencies. For a
discussion of such risks and uncertainties, which could cause
actual results to differ from those contained in the
forward-looking statements regarding ADVENTRX, see the section
titled "Risk Factors" in ADVENTRX's last quarterly report on Form
10-Q, as well as other reports that ADVENTRX files from time to
time with the Securities and Exchange Commission. All
forward-looking statements regarding ADVENTRX are qualified in
their entirety by this cautionary statement. ADVENTRX undertakes no
obligation to release publicly any revisions, which may be made to
reflect events or circumstances after the date hereof. DATASOURCE:
ADVENTRX Pharmaceuticals, Inc. CONTACT: Andrea Lynn of ADVENTRX
Pharmaceuticals, +1-858-552-0866 Web site:
http://www.investorcalendar.com/IIF/CustomEvent/90563/index.asp
http://www.adventrx.com/ Company News On-Call:
http://www.prnewswire.com/comp/920134.html
Copyright
Adventrx (AMEX:ANX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Adventrx (AMEX:ANX)
Historical Stock Chart
From Sep 2023 to Sep 2024